235 related articles for article (PubMed ID: 9690697)
1. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.
Carrillo JA; Herraiz AG; Ramos SI; Benítez J
J Clin Psychopharmacol; 1998 Aug; 18(4):311-6. PubMed ID: 9690697
[TBL] [Abstract][Full Text] [Related]
2. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia.
Frazier JA; Cohen LG; Jacobsen L; Grothe D; Flood J; Baldessarini RJ; Piscitelli S; Kim GS; Rapoport JL
J Clin Psychopharmacol; 2003 Feb; 23(1):87-91. PubMed ID: 12544379
[TBL] [Abstract][Full Text] [Related]
3. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.
Ammar H; Chadli Z; Mhalla A; Khouadja S; Hannachi I; Alshaikheid M; Slama A; Ben Fredj N; Ben Fadhel N; Ben Romdhane H; Chaabane A; Boughattas NA; Gaha L; Zarrouk L; Aouam K
Pharmacogenomics J; 2021 Oct; 21(5):551-558. PubMed ID: 33731885
[TBL] [Abstract][Full Text] [Related]
5. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
[TBL] [Abstract][Full Text] [Related]
6. The Potential Role of
Demirbugen Oz M; Ozdemir F; Tok KC; Dural E; Kir Y; Ulusoy M; Gumustas M; Baskak B; Suzen HS
Expert Opin Drug Metab Toxicol; 2023; 19(5):319-327. PubMed ID: 37269349
[TBL] [Abstract][Full Text] [Related]
7. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
[TBL] [Abstract][Full Text] [Related]
9. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients.
Lee ST; Ryu S; Nam HJ; Lee SY; Hong KS
Int Clin Psychopharmacol; 2009 May; 24(3):139-44. PubMed ID: 19194306
[TBL] [Abstract][Full Text] [Related]
10. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients.
Doude van Troostwijk LJ; Koopmans RP; Vermeulen HD; Guchelaar HJ
Eur J Pharm Sci; 2003 Dec; 20(4-5):451-7. PubMed ID: 14659489
[TBL] [Abstract][Full Text] [Related]
11. Clozapine metabolism rate as a possible index of drug-induced granulocytopenia.
Mauri MC; Rudelli R; Bravin S; Gianetti S; Giuliani E; Guerrini A; Orlandi R; Invernizzi G
Psychopharmacology (Berl); 1998 Jun; 137(4):341-4. PubMed ID: 9676893
[TBL] [Abstract][Full Text] [Related]
12. Whole saliva and plasma levels of clozapine and desmethylclozapine.
Dumortier G; Lochu A; Zerrouk A; Van Nieuwenhuyse V; Colen de Melo P; Roche Rabreau D; Degrassat K
J Clin Pharm Ther; 1998 Feb; 23(1):35-40. PubMed ID: 9756110
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia.
Xiang YQ; Zhang ZJ; Weng YZ; Zhai YM; Li WB; Cai ZJ; Tan QR; Wang CY
Schizophr Res; 2006 Apr; 83(2-3):201-10. PubMed ID: 16524698
[TBL] [Abstract][Full Text] [Related]
14. Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.
Ortega-Vázquez A; Mayen-Lobo YG; Dávila-Ortiz de Montellano DJ; Tristán-López L; Aviña-Cervantes CL; Ríos C; López-López M; Monroy-Jaramillo N
Drug Dev Res; 2021 Aug; 82(5):685-694. PubMed ID: 33336447
[TBL] [Abstract][Full Text] [Related]
15. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
[No Abstract] [Full Text] [Related]
16. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations.
Augustin M; Schoretsanitis G; Pfeifer P; Gründer G; Liebe C; Paulzen M
Schizophr Res; 2019 Aug; 210():143-148. PubMed ID: 31182321
[TBL] [Abstract][Full Text] [Related]
17. Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia.
Vaquero-Baez M; Díaz-Ruíz A; Tristán-López L; Aviña-Cervantes C; Torner C; Ramírez-Bermúdez J; Montes S; Ríos C
BMC Psychiatry; 2019 Oct; 19(1):295. PubMed ID: 31597566
[TBL] [Abstract][Full Text] [Related]
18. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia.
Tang YL; Mao P; Li FM; Li W; Chen Q; Jiang F; Cai ZJ; Mitchell PB
Br J Clin Pharmacol; 2007 Jul; 64(1):49-56. PubMed ID: 17298477
[TBL] [Abstract][Full Text] [Related]
19. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.
Lee ST; Ryu S; Kim SR; Kim MJ; Kim S; Kim JW; Lee SY; Hong KS
J Clin Psychopharmacol; 2012 Aug; 32(4):441-8. PubMed ID: 22722500
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine.
Chang WH; Augustin B; Lane HY; ZumBrunnen T; Liu HC; Kazmi Y; Jann MW
Psychopharmacology (Berl); 1999 Jul; 145(1):91-8. PubMed ID: 10445377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
